ABSTRACT
of the ovary. Tumors in which only clear cells are found on histological examination are defined as pure clear cell carcinomas, while admixtures of ovarian clear cell carcinoma with, for example, serous, mucinous, endometrioid or other tumor cells, are classified as clear cell carcinomas mixed with other histotypes 1 .
Background

Epidemiology
Clear cell carcinoma of the ovary represents 5% to 25% of all epithelial ovarian cancers, depending on geographic location 2 . Substantial ethnic and/or racial differences in the distribution of different histological types of ovarian cancer are described in the literature. In Japan, ovarian clear cell carcinoma is more common than in western countries 3 . Patients with clear cell cancer are younger than those with high-grade serous cancers (median age 55 vs 64 years) 2, 4 . A large proportion (25-58%) of clear cell carcinomas are diagnosed in women who have endometriosis [5] [6] [7] . About 30% of clear cell carcinomas show evidence of the tumor developing from endometriosis 8, 9 , and pathologists support the theory that endometriosis might be a precursor of clear cell carcinoma 10 . According to the dualistic model of epithelial ovarian carcinogenesis, clear cell carcinomas are Type-I tumors. Type-I tumors typically develop from benign tissue that implants in the ovary, for example, from endometrial implants in case of clear cell carcinoma. The implanted benign tissue may subsequently undergo malignant transformation in a slow, stepwise fashion. Type-II tumors (i.e. high-grade serous carcinomas) develop from intraepithelial carcinomas in the Fallopian tube, disseminating to the ovary and extra-ovarian sites with aggressive behavior 10 .
Microscopy
Clear cell carcinomas display different microscopic patterns: papillary, tubulo-cystic and solid. Most tumors display a combination of all these patterns 9 . They are considered to have arisen from endometriosis if Sampson's criteria of malignant transformation are fulfilled 11 . Usually the focus of malignant transformation is found in a large protrusion of solid tissue in the cyst cavity 12 . All clear cell carcinomas are considered to be high-grade tumors 13 .
Macroscopy
Clear cell carcinomas are usually large, up to 30 cm in diameter, with a mean size of 13-15 cm 12 . In most (92%) cases, they appear as unilateral masses 12 . They range from solid, to solid and cystic, to mainly cystic with fleshy, pale yellow nodules 13 . Clear cell carcinomas developing from endometriosis display the features of a cyst containing chocolate-colored fluid with a thickened polypoid or nodular area in the wall 12 .
Clinical features and prognosis
Symptoms are usually explained by the presence of a pelvic or abdominal mass, and not by peritoneal spread 12 . A large unilateral ovarian mass is typically found, omentum and mesentery are seldom involved, and ascites and carcinomatosis are rare 10, 13 . Reports show that 57-81% of clear cell carcinomas are diagnosed at FIGO Stage I or II 14, 15 . Clear cell carcinomas have excellent prognosis when they are confined to the ovary. However, advanced stage clear cell carcinoma has a poorer prognosis than other epithelial ovarian cancers. This seems to be explained by clear cell carcinoma being less responsive to platinum-based chemotherapy 14, 16 . Pectasides et al. 17 reported that the response rate to chemotherapy is lower for advanced stages of clear cell ovarian carcinoma than for advanced stages of serous carcinomas (45% vs 81%, respectively).
METHODS
This was a retrospective multicenter study including patients from 11 ultrasound centers (listed at the end of the main text). From the International Ovarian Tumor Analysis (IOTA) database, we identified patients with a histological diagnosis of ovarian pure clear cell carcinoma who had undergone preoperative ultrasound examination between 1999 and 2016 [18] [19] [20] [21] . Additional patients diagnosed with pure clear cell carcinoma between 1999 and 2016 and with available complete preoperative ultrasound reports were identified retrospectively from the databases of the departments of gynecological oncology in the participating centers. All patients had undergone preoperative ultrasound examination by an experienced ultrasound examiner who used the IOTA examination and measurement techniques and terminology 22 to describe the ultrasound images of the adnexal masses. The ultrasound examinations were carried out using high-end ultrasound equipment. The frequency of the vaginal probes varied between 5.0 and 9.0 MHz and that of the abdominal probes between 3.5 and 5.0 MHz.
In the case of bilateral adnexal masses, the mass with the most complex ultrasound morphology was used in the analysis. If both masses had similar ultrasound morphology, the largest mass or the one most easily accessible by ultrasound was included. According to the IOTA terminology, papillary projections were defined as solid tissue protruding into the cyst cavity from the cyst wall or from a septum with a height of 3 mm or more 22 . The largest solid component other than a papillary projection (i.e. solid tissue not protruding into the cyst cavity) was also measured. In some cases, a papillary projection was the largest solid component. If this was the case, the papillary projection was recorded and measured both as a papillary projection and as the largest solid component, in agreement with the IOTA consensus statement 22 . The presence of ascites and fluid in the pouch of Douglas was noted. Vascularization of the tumors on color Doppler was described using the IOTA color score: no detectable blood flow (color score = 1), minimal blood flow (color score = 2), moderate blood flow (color score = 3) or abundant blood flow (color score = 4) 22 . The specific diagnosis suggested by the ultrasound examiner in the original ultrasound report was recorded.
For women included in the IOTA studies, clinical and ultrasound information was obtained from the IOTA database, which contains data collected prospectively. For women who had been examined outside the IOTA studies, and in the case of missing information in the IOTA database, information was retrieved retrospectively from patient records and entered into an Excel file (Microsoft Office Excel 2007, Redmond, WA, USA) by the principal investigator at each center.
In addition to using the information collected in the IOTA database and patient records, one author with more than 10 years' experience in gynecological ultrasound (F.M.), assessed ultrasound images using pattern recognition 23 , with the aim of identifying any typical ultrasound patterns of ovarian pure clear cell carcinoma. Only images of good quality were used for the pattern recognition assessment.
Final histology, FIGO stage 24 , the presence of tumor developing from endometriosis (as judged by the local pathologist) and the presence of histologically confirmed endometriosis in the ipsilateral ovary or elsewhere in the pelvis were recorded. Clinical and ultrasound information was entered into a dedicated Excel file. Results are presented as absolute frequency (percentage) for nominal variables and as median (range) for continuous variables. The statistical difference in continuous data was determined using Mann-Whitney U-test or Kruskal-Wallis test and that in nominal data using χ 2 or Fisher's exact test, as appropriate. Statistical analyses were performed using the Statistical Package for Social Sciences software (PASW version 20.0, SPSS Statistic, IBM corp., New York, NY, USA). Two-sided tests were used and the significance level was set at P < 0.05.
RESULTS
We identified 105 patients with pure clear cell cancer of the ovary from the IOTA databases and another 47 patients examined outside the IOTA studies. There were no substantial differences in clinical or ultrasound characteristics between cases examined within and those examined outside the IOTA studies, except that fewer IOTA patients reported a history of oophorectomy, and more patients in the IOTA studies had ascites and free fluid in the pouch of Douglas (Tables S1 and S2 ). Therefore, results are presented for all 152 patients together.
Information regarding the presence, site and type of histologically confirmed pelvic endometriosis was available for 130 of the 152 patients. Endometriosis was found in 54/130 (41.5%) patients. In 24/130 (18.5%) of these, the pathologist judged the clear cell carcinoma to have developed from endometriosis, in 10/130 (7.7%) there was endometriosis in the ovary harboring the clear cell carcinoma but no signs of the cancer developing from endometriosis and in 20/130 (15.4%), endometriotic lesions were noted elsewhere in the pelvis.
Demographic data and tumor characteristics of all 152 cases are shown in Table 1 Demographic background data and tumor characteristics of the 130 cases with clear cell carcinoma for which information was available on endometriosis at histological examination are shown in Table 1 . There were no substantial differences in clinical characteristics, except for age, between the four groups: patients without endometriosis, patients with evidence of tumor developing from endometriosis, patients with endometriosis in the same ovary but no evidence of tumor developing from endometriosis and patients with endometriosis elsewhere in the pelvis. Patients with cancer developing from endometriosis were younger than those with cancer not developing from endometriosis (median 47.5 vs 55.0 years, respectively).
Sonographic characteristics of the pure clear cell carcinomas in all 152 patients are described in Table 2 . The original ultrasound examiner suggested a diagnosis of benign lesion in 7/152 (4.6%) cases, borderline ovarian tumor in 28/152 (18.4%) cases and malignant tumor in 117/152 (77.0%) cases. Two of the seven tumors misdiagnosed as benign were suspected to be endometriomas, two to be fibromas/fibrothecomas, one to be a teratoma, one an abscess and, in one case, a specific diagnosis was not suggested. Ultrasound images were available for two of the seven misclassified cancers ( Figure S1 ).
Ultrasound characteristics of patients with and those without confirmation of pelvic endometriosis on histological examination are shown in Table 2 and Figure 2 . There were no substantial differences in ultrasound characteristics between the four groups of patients, except for the type of echogenicity of cyst fluid. Clear cell cancers developing from endometriosis more often contained cyst fluid with ground-glass echogenicity than those not developing from endometriosis (10/20 (50.0%) vs 7/57 (12.3%) in those without endometriosis, vs 3/8 (37.5%) in those with endometriosis in the same ovary but no evidence of tumor developing from endometriosis and vs 3/14 (21.4%) in those with endometriosis elsewhere in the pelvis). Ultrasound images of high quality were available for 77/152 (50.7%) clear cell carcinomas. Using pattern recognition, no specific ultrasound pattern could be detected.
DISCUSSION
We have described the clinical and ultrasound characteristics of ovarian pure clear cell carcinomas. Median age at diagnosis was 53.5 years, 42.8% of the patients were premenopausal, and most tumors were FIGO Stage I. Most clear cell cancers were large unilateral tumors, all manifested solid components and almost 40% contained papillary projections. However, using pattern recognition, no ultrasound pattern specific to clear cell carcinoma could be detected. In 41.5% of patients, pelvic endometriosis was confirmed histologically and, in almost half of these, the pathologist judged the cancer to have developed from endometriosis. Patients with clear cell cancer developing from endometriosis were younger than those with clear cell cancer not developing from endometriosis. On ultrasound, clear cell carcinomas developing from endometriosis more often manifested ground-glass echogenicity of cyst fluid, but no other morphological differences were observed.
To the best of our knowledge, this is the largest study describing ultrasound features of ovarian pure clear cell carcinomas. One strength of this study is that it is multicenter and large, which increases the likelihood of our results being generalizable. Another strength is that all tumors were described in a standardized manner using IOTA terminology. A limitation of this study is that it is retrospective. Ultrasound images were not available for all Data presented as n (%), median (range) or n/N (%). *Comparisons, between four groups with histological information on endometriosis, by Kruskal-Wallis test for continuous variables and χ 2 or Fisher's exact test for nominal variables, as appropriate. †Data available for 62/63 cases in 'All' group and 51/52 cases with histological information on endometriosis available (N). ‡Data available for 115/116 cases in 'All' group. §Solid component includes papillary projections; data available for 151 cases overall. ¶Data available for 56/58 cases in 'All' group and 45/47 cases with histological information on endometriosis available. **Data available for 150 cases in 'All' group and 128 cases with histological information on endometriosis available. † †Six rare malignant tumors and one tubal carcinoma. cases, and this may have limited the possibility to detect ultrasound features specific to clear cell cancer. The clinical findings of the current study agree with those of others 12, 13 who noted that, compared with high-grade serous ovarian carcinomas, clear cell carcinomas present more often at an early stage, in patients who are younger and in premenopausal women. In agreement with Scarfone et al. 25 , we found that patients with clear cell carcinoma showing evidence of the tumor developing from endometriosis were younger than other patients with clear cell carcinomas. Our ultrasound results agree well with the macroscopic appearance of clear cell carcinomas described in pathology textbooks: most were large, unilateral tumors described as solid, both solid and cystic or mainly cystic with solid nodules 13 . Our ultrasound findings agree with those of Alcazar et al. 26 who described the ultrasound features of 16 clear cell carcinomas and found that 15 were unilateral masses with solid components vascularized on color Doppler examination. Testa et al. 27 described the ultrasound findings in 15 malignancies developing from endometriomas. In their study, the proportion of tumors with papillary projections was higher than in the clear cell cancers developing from endometriomas in ours (86.7% vs 41.7%). This might be explained by Testa et al. 27 including not only clear cell carcinomas (n = 6), but also endometrioid cancers (n = 5) and borderline tumors (n = 4) developing from endometriosis.
Clear cell carcinomas have some clinical and pathological features similar to those of endometrioid carcinomas 28 . Both are diagnosed more often in premenopausal patients than are the much more common serous carcinomas 12, 29 and both are frequently found at an early stage (FIGO Stage I). Both histotypes are considered Type-I tumors with indolent behavior, and endometriosis has been described as a possible precursor for both 10 . Endometrioid ovarian cancers and ovarian pure clear cell cancers also have similar ultrasound characteristics. Most are large unilateral tumors with solid components, and papillary projections are common 28 . Papillary projections are particularly common in endometrioid (46.9%) 28 and clear cell (41.7%) carcinomas developing from endometriosis. Papillary projections are typical ultrasound features of serous and mucinous endocervical-type borderline tumors 30 , and this could explain why many clear cell carcinomas (18%) and endometrioid ovarian cancers (11%) 28 were misdiagnosed as borderline tumors by the original ultrasound examiner. In our study on endometrioid ovarian cancers, we found that many endometrioid cancers not developing from endometriosis had a cockade-like appearance on ultrasound, i.e. a large central solid component entrapped within locules 28 . For clear cell carcinomas, we could not identify any specific ultrasound pattern. Because endometrioid and clear cell cancers of the ovary present similarly clinically and look similar on ultrasound, we do not believe that it would be possible to discriminate between these two cancer types preoperatively. However, it should be possible to distinguish endometrioid or clear cell cancer of the ovary from serous ovarian cancer (especially high-grade serous cancer) and mucinous ovarian cystadenocarcinoma because of differences in clinical presentation and ultrasound features 28, 29, 31 . It should at least be possible to evaluate which diagnosis is the most likely. High-grade serous carcinomas are more often bilateral than clear cell carcinomas; they are multilocular-solid or solid lesions that very rarely contain papillary projections 29 . Mucinous ovarian carcinomas are much larger than serous, endometrioid and clear cell carcinomas, virtually always unilateral and contain a very large number of cyst locules, but papillary projections are very rare 31 . Preoperative discrimination between different types of ovarian malignancy can be of clinical importance. For example, knowing the most likely type of malignancy may affect patient counseling (prognosis, most likely type of surgery, possibility of conservative surgery in young patients with Stage-I clear cell carcinoma 32 , which tumor markers to test). Clear cell carcinoma is less sensitive to platinum-based chemotherapy 14, 16 than serous and endometrioid adenocarcinomas and, if it were possible to identify clear cell tumors preoperatively, this could assist the oncology surgeon in making maximal efforts to obtain zero residual disease. The typical ultrasound appearance of different ovarian malignancies has been described in the Imaging in Gynecological Disease series of this journal (see Virtual Issue https://obgyn.onlinelibrary.wiley.com/doi/toc/10.1002/ (ISSN)1469-0705.IMAGINGINGYNECOLOGICALDIS EASE) 28, 29, 31, [33] [34] [35] [36] [37] [38] . It remains to be shown in prospective studies if different types of ovarian malignancy, including epithelial ovarian cancer, i.e. serous, mucinous, endometrioid, clear cell and undifferentiated cancers, can be distinguished on the basis of clinical information and ultrasound appearance. However, before starting any prospective study, the typical ultrasound appearance of different types of ovarian malignancy should be identified.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Table S1
Clinical and tumor characteristics in 152 cases of pure ovarian clear cell carcinoma, overall and according to whether they were included in International Ovarian Tumor Analysis (IOTA) studies Table S2 Ultrasound characteristics and diagnosis suggested by the original ultrasound examiner in 152 cases of pure ovarian clear cell carcinoma, overall and according to whether they were included in International Ovarian Tumor Analysis (IOTA) studies Figure S1 Ultrasound images of two pure clear cell carcinomas suggested to be benign lesions by original ultrasound examiner. Abscess was suspected in (a) and endometrioma in (b).
